Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide

Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide

The prevention of chronic graft-versus-host disease (cGVHD) is important for recipients of hematopoietic stem-cell transplantation (HSCT). As one of the etiologies, the relationship between early T-cell recovery and subsequent cGVHD development has been the focus of attention. Recently, letermovir (...

Full description

Bibliographic Details
Main Authors: Toshiki Terao, Ken-ichi Matsuoka, Kentaro Narita, Takafumi Tsushima, Satoshi Yuyama, Ayumi Kuzume, Rikako Tabata, Daisuke Miura, Masami Takeuchi, Kosei Matsue
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
letermovir
chronic graft-versus-host disease
cytomegalovirus
haploidentical stem-cell transplantation
post-transplant cyclophosphamide
HLA-DR+ activated T-cell
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.666774/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.666774/full

Similar Items